-
Pitavastatin (NK-104): In Vitro Protocol Guide
2026-08-16
Pitavastatin (NK-104, SKU B1124) provides a defined HMG-CoA reductase inhibition tool for cholesterol-biosynthesis assays and related cell-based workflows. It is best used in vitro or in biochemical studies, not as a substitute for clinical treatment or unvalidated animal dosing.
-
Recombinant Human Oncostatin M in Fibroblast Aging
2026-08-15
Discover how Recombinant Human Oncostatin M can be integrated into fibroblast-state and cytokine-response studies. This article combines product-specific assay design with mitochondrial senescence readouts from a 2025 dermal fibroblast study to support more discriminating experiments.
-
Novobiocin Workflows for Antimicrobial Research
2026-08-14
Novobiocin combines DNA gyrase B ATPase inhibition with Hsp90-directed activity, giving researchers a flexible tool for bacterial, parasitic, and carefully controlled antiviral assays. This guide translates those mechanisms into practical workflows, assay controls, formulation choices, and troubleshooting strategies.
-
Streptozotocin Workflows for Diabetes Models
2026-08-14
Streptozotocin, or STZ, enables controlled β-cell injury for experimental diabetes mellitus induction, therapeutic screening, and complication research. This practical guide connects model-building decisions with painful diabetic neuropathy assays, including TBK1–microglia pyroptosis readouts, while emphasizing dose selection, reagent stability, and phenotype validation.
-
Proteinase K for DNA Preparation: Mechanism and Use
2026-08-13
Proteinase K is a broad-spectrum serine protease used for genomic DNA isolation enzyme workflows and enzyme contaminant removal for DNA prep. Its resistance to SDS and EDTA supports protein hydrolysis in molecular biology while controlled digestion helps preserve DNA integrity during protein digestion.
-
SW033291: Designing Better Regeneration Assays
2026-08-13
SW033291 is a potent 15-PGDH inhibitor for studying prostaglandin E2 elevation, hematopoiesis stimulation, and tissue repair. This guide focuses on assay design, target-engagement controls, and how recent muscle-regeneration findings should shape experimental interpretation.
-
IEM 1460: AMPA Receptor Blocker Workflows
2026-08-12
IEM 1460 enables controlled AMPA receptor inhibition assays for dissecting excitotoxicity, synaptic signaling, and neuroprotection. This workflow-focused guide connects receptor-selective experiments with lessons from a recent in vivo glutamate-receptor study while clearly separating validated findings from practical optimization recommendations.
-
KG-501 for CREB–CBP Transcription Studies
2026-08-12
KG-501 provides a practical way to test CREB–CBP coactivator recruitment in cancer and macrophage assays, complementing receptor-level pathway experiments. This workflow connects transcriptional coactivator disruption with proliferation, differentiation, inflammatory polarization, and colorectal cancer research while preserving essential controls for compound solubility and pathway specificity.
-
MitMAB: Causal Mapping of Organoid Uptake
2026-08-11
MitMAB enables causal analysis of dynamin-dependent uptake in intestinal organoid systems. This article connects the compound’s mechanism with organoid orientation, extracellular vesicle biology, and more defensible intracellular trafficking research decisions.
-
MALAT1 Levels Shape TDP-43 RNA Binding and Cell Viability
2026-08-11
The reference study shows that MALAT1 abundance influences both cell survival and the distribution of TDP-43 binding across mRNA transcripts. Its results support a dosage-sensitive RNA–protein network in which MALAT1 can modify TDP-43 function, including during MPP+-induced neuronal stress.
-
NSC 87877: Shp2 Inhibitor Workflow
2026-08-10
NSC 87877 is a Shp2-focused small molecule for dissecting phosphatase activity, EGF–Ras–Erk signaling, leukemia-cell responses, and SHP2-linked neuroinflammation. This workflow emphasizes assay controls, concentration planning, and the distinction between direct pharmacological inhibition and tFUS-mediated regulation after ischemic stroke.
-
Spiroplasma Entry into S2 Cells and Endocytic Routes
2026-08-09
Wei et al. established a Drosophila Schneider 2 cell model showing that Spiroplasma eriocheiris invades insect cells through clathrin-mediated endocytosis and macropinocytosis. Pharmacological pathway inhibition, cytoskeletal perturbation, and infection-associated stress measurements together provide a useful framework for studying this poorly characterized host–pathogen interaction.
-
EZ Cap™ Cy5 EGFP mRNA (5-moUTP) Workflow
2026-08-08
Build a quantitative mRNA delivery and translation efficiency assay around one payload with two independent readouts: Cy5 tracks intracellular trafficking, while EGFP reports functional translation. This workflow also shows how polymer-micelle binding data can guide nanoparticle screening, macrophage studies, and delivery-system troubleshooting.
-
Ang II–HIF-1α–HILPDA Axis in NPC Radioresistance
2026-08-07
The reference study identifies local angiotensin II as a regulator of ferroptosis and radiotherapy resistance in nasopharyngeal carcinoma through an AGT–HIF-1α–HILPDA feedback circuit. Its combination of resistant cell models, mechanistic assays, tissue analysis, and xenograft experiments supports dual Ang II blockade and ferroptosis induction as a radiosensitization strategy, while also defining important limits for translation.
-
FAISL lncRNA Blocks FAK Proteolysis to Drive TNBC Progressio
2026-08-07
The reference study reveals that the long noncoding RNA FAISL promotes progression and metastasis of triple negative breast cancer (TNBC) by inhibiting Calpain 2-mediated proteolysis of focal adhesion kinase (FAK). This mechanism highlights FAISL as a critical regulator of FAK stability and a potential therapeutic target in aggressive breast cancers.